CKD Drug Development Map 2026: Approval Wave & the Race for Next-Gen Dominance

Introduction

The CKD (Chronic Kidney Disease) therapeutics market is undergoing a historic transformation in the mid-2020s. Following the "first wave" of SGLT2 inhibitors and Finerenone establishing themselves as standard of care, 2025-2026 has seen a simultaneous convergence of IgA nephropathy approval waves, Phase 3 competition among aldosterone synthase inhibitors (ASIs), and endothelin receptor antagonist (ERA) label expansions.

This article analyzes the CKD landscape from a business perspective—who is winning, who is struggling, and where the market is heading. For detailed clinical data and mechanisms of action, see our comprehensive CKD drug clinical and mechanism guide.

1. Market Overview: Structural Shifts in CKD Therapeutics

1.1 Market Size & Growth Drivers

The global CKD therapeutics market is estimated at approximately $15 billion in 2025, with projections exceeding $30 billion by 2030. Three structural factors drive this explosive growth:

1. Expanding patient population: ~800 million people worldwide (about 10% of adults) have CKD, with prevalence rising alongside aging populations and the diabetes/obesity epidemic.
2. Treatment paradigm shift: A transition from symptomatic blood pressure management to disease-modifying therapies (DMTs) that directly target fibrosis and inflammation.
3. Advances in diagnostics: Wider adoption of UACR and eGFR screening is identifying treatable patients earlier, expanding the addressable market.

1.2 Competitive Landscape at a Glance

Segment	Key Players	2025-2026 Status
Established SoC	Bayer (Finerenone), AstraZeneca (Dapagliflozin), Novo Nordisk (Semaglutide)	Embedded in KDIGO guidelines; market foundation established
IgA Nephropathy	Novartis (Atrasentan, Iptacopan), Otsuka (Sibeprenlimab), Travere (Sparsentan)	Approval wave: 4 drugs approved/filed in 2024-2025
Next-Gen ASI	AstraZeneca (Baxdrostat), BI (Vicadrostat), Mineralys (Lorundrostat)	Phase 2→3 transition: Three-way race
ERA	AstraZeneca (Zibotentan), Novartis (Atrasentan)	Exploring label expansion into diabetic kidney disease

2. Key Events 2025-2026: Approvals, Successes, & Setbacks

2.1 Approvals & Phase 3 Successes (Green Light)

Sparsentan (Travere Therapeutics) — FDA Full Approval 2024

• First-in-class dual ET/AT1 antagonist approved for IgA nephropathy
• 2-year PROTECT data confirmed sustained eGFR decline reduction
• FSGS label expansion (DUPLEX trial) in progress
• Travere's flagship commercial asset

Atrasentan (Novartis) — FDA Accelerated Approval 2025

• ALIGN trial demonstrated efficacy in IgA nephropathy
• Novartis acquired Chinook Therapeutics for ~$3.7B in 2021 to obtain this asset
• Part of a "dual-asset strategy" alongside Iptacopan (complement Factor B inhibitor)

Sibeprenlimab / Voyxact (Otsuka / Visterra) — FDA Approval 2025

• APRIL-targeting antibody for IgA nephropathy
• Monthly subcutaneous injection offers convenience differentiation
• A new pillar for Otsuka's nephrology franchise

Iptacopan / Fabhalta (Novartis) — C3 Glomerulopathy Approval 2025

• Complement Factor B inhibitor: 38% proteinuria reduction in APPLAUSE-IgAN
• Oral formulation differentiates against injectable competitors
• Sequential approvals in IgA nephropathy and C3G strengthen Novartis's portfolio

Finerenone Label Expansion — FINE-ONE Trial Success

• Demonstrated UACR reduction in T1D-associated CKD
• T1D label expansion anticipated in 2026
• Further solidifies Bayer's renal franchise

2.2 Phase 3 in Progress (Key Watchlist)

Vicadrostat / BI 690517 (Boehringer Ingelheim)

• ASI frontrunner by trial scale
• Phase 3 EASi-KIDNEY: ~11,000 patients across 15-20 countries
• Empagliflozin combination strategy to compete with AZ's Baxdrostat

Baxdrostat (AstraZeneca)

• Dapagliflozin combination Phase 3 in progress
• AZ acquired CinCor Pharma for ~$1.8B in 2023 to obtain this asset
• "In-house complete package" (SGLT2i + ASI) is a strategic advantage

Zibotentan + Dapagliflozin (AstraZeneca)

• ERA + SGLT2i combination to offset fluid retention risk
• ZENITH High Proteinuria Phase 3 ongoing
• If successful, AZ builds a CKD "triple stack" (SGLT2i + ASI + ERA)

2.3 Notable M&A Activity

CKD has seen a wave of multi-billion-dollar acquisitions in 2023-2025, signaling big pharma's conviction that this is the next major market opportunity.

Year	Acquirer	Target	Deal Value	Key Asset
2023	Novartis	Chinook Therapeutics	~$3.7B	Atrasentan (ERA)
2023	AstraZeneca	CinCor Pharma	~$1.8B	Baxdrostat (ASI)
2023	Otsuka	Visterra (full integration)	Undisclosed	Sibeprenlimab (APRIL)

These acquisitions underscore the consensus view that CKD/renal fibrosis represents the next blockbuster therapeutic area.

3. Competitive Landscape Visualization

Legend:

• Green: Approved
• Blue: Phase 3 in progress
• Yellow: Phase 2 (transitioning)

4. Strategic Analysis: Corporate Positioning

Novartis — IgA Nephropathy "Dual-Asset" Play

Novartis holds two mechanistically distinct drugs—Atrasentan (ERA) and Iptacopan (complement Factor B inhibitor)—both approved for IgA nephropathy. The $3.7B Chinook acquisition is paying dividends, and the company is well-positioned to dominate the IgA market through combination strategies and head-to-head differentiation.

AstraZeneca — CKD "Full-Stack" Strategy

AstraZeneca is building a vertically integrated CKD portfolio: Dapagliflozin (SGLT2i) as the foundation, with Baxdrostat (ASI) and Zibotentan (ERA) layered on top. Owning all three assets in-house enables seamless combination trial design and unified commercial messaging.

Bayer — Finerenone "Label Expansion" Play

Bayer is methodically expanding Finerenone's addressable market from T2D-CKD to T1D-CKD. The CONFIDENCE trial data (52% UACR reduction with Finerenone + SGLT2i) provides powerful ammunition for combination therapy positioning.

Boehringer Ingelheim — "IPF + CKD" Cross-Disease Approach

Following Nerandomilast approval in IPF, Boehringer is advancing Vicadrostat (ASI) in CKD. This "pan-fibrosis" approach positions the company uniquely across multiple fibrotic diseases, potentially enabling cross-indication learnings and shared commercial infrastructure.

5. What to Watch: 2026H2 and Beyond

1. ASI race resolution: Vicadrostat (BI) and Baxdrostat (AZ) Phase 3 readouts will determine first-mover advantage in this high-stakes segment.
2. Guideline updates: KDIGO 2026-2027 revisions may formally recommend quadruple therapy (RAS + SGLT2i + Finerenone + GLP-1RA), reshaping prescribing patterns.
3. IgA nephropathy market maturation: With 4 approved drugs, differentiation by route of administration (oral vs. injectable), mechanism, and long-term data becomes critical.
4. Biosimilar impact: Dapagliflozin patent expiry timelines (varying by geography from 2026 onward) could reshape the SGLT2i market.

6. Conclusion

The CKD therapeutics market has decisively transitioned from a "one-to-two drug era" to a "layered combination era" in 2025-2026. Novartis's IgA dual-asset play, AstraZeneca's full-stack strategy, and Boehringer's pan-fibrosis approach represent clearly differentiated corporate visions competing for market leadership.

For companies developing new CKD therapeutics, demonstrating add-on efficacy over this already-powerful standard of care is the critical success factor in clinical trial design. At the preclinical stage, selecting the appropriate renal fibrosis model aligned with a candidate's differentiation strategy—whether anti-fibrotic, anti-inflammatory, or metabolic—remains the key to translational success.

References & Clinical Trial Information

Established Standard of Care

1. Bakris GL, et al. Effect of Finerenone on CKD Outcomes in T2D. N Engl J Med. 2020;383:2219-2229. (FIDELIO-DKD: NCT02540993)

2. Heerspink HJL, et al. Dapagliflozin in CKD. N Engl J Med. 2020;383:1436-1446. (DAPA-CKD: NCT03036150)

3. Perkovic V, et al. Semaglutide in CKD. N Engl J Med. 2024. (FLOW: NCT03819153)

IgA Nephropathy & Complement

4. Atrasentan ALIGN Phase 3: NCT04573478

5. Iptacopan APPLAUSE-IgAN Phase 3: NCT04578834

6. Sibeprenlimab VISIONARY Phase 3: NCT05248646

ASI (Aldosterone Synthase Inhibitors)

7. Vicadrostat EASi-KIDNEY Phase 3: NCT06531824

8. Baxdrostat + Dapagliflozin Phase 3: NCT06268873

ERA (Endothelin Receptor Antagonists)

9. Zibotentan + Dapagliflozin ZENITH Phase 3: NCT06087835

Combination Therapy

10. Green JB, et al. Finerenone and Empagliflozin in DKD. N Engl J Med. 2025. (CONFIDENCE: NCT05254002)

Related Articles

• CKD Drug Clinical Data & Mechanism Guide
• Anti-Fibrotic Drug Pipeline: Cross-Disease Approaches
• IPF Drug Development Map 2025
• UUO Model: Gold Standard for Renal Fibrosis
• Adenine-Induced CKD Model